{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:35:06Z","timestamp":1787762106239,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Many studies have investigated most cancer types - associations with systemic inflammatory response (SIR) parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>This study investigated predictive values of SIR parameters in oncological outcomes and survival \u2013 to primary non-muscle-invasive bladder cancer (NMIBC) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>We analyzed 74 primary NMIBC patients. Clinical features, laboratory results, and tumor characteristics were recorded. In addition, the neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), serum C-reactive protein, albumin-to-globulin ratio (AGR), and modified Glasgow prognostic scores (mGPS) were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The - mean age of the patients was - 67.41 \u00b1 11.31 years, and the follow-up duration was 38.77 \u00b1 19.53 months. We \u2013 found no significant NLR, CRP, and AGR \u2013 correlations with tumor characteristics and oncological outcomes. There were significant \u2013 correlations between MLR and pathological-T-stage and the PLR, pathological-T-stage, and tumor count. Carcinoma\n                      <jats:italic toggle=\"yes\">in situ<\/jats:italic>\n                      was associated with a high mGPS. Multivariate analysis revealed no significant \u2013 correlations between systemic inflammatory response parameters and oncological outcomes. Patients with a high mGPS had poor cancer-specific survival. Increased NLR was associated with reduced overall survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study revealed no significant correlation between SIR parameters and oncological outcomes. Therefore, we need more reliable indicators than SIR parameters in NMIBC patients in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njcp.njcp_399_22","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T22:23:57Z","timestamp":1687559037000},"page":"591-598","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Can Peripheral Blood Systemic Immune Response Parameters Predict Oncological Outcomes in Patients with Non-Muscle-Invasive Bladder Cancer?"],"prefix":"10.4103","volume":"26","author":[{"given":"A","family":"\u00c7aglayan","sequence":"first","affiliation":[{"name":"Department of Urology, \u00c7i\u011fli Training and Research Hospital, Izmir Bak\u0131r\u00e7ay University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MO.","family":"Horsanali","sequence":"additional","affiliation":[{"name":"Deparment of Urology, Faculty of Medicine, Izmir Bak\u0131r\u00e7ay University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"R1-20240907","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3233\/BLC-170138","article-title":"Defining priorities to improve patient experience in non-muscle invasive bladder cancer","volume":"4","author":"Garg","year":"2018","journal-title":"Bladder Cancer"},{"key":"R2-20240907","doi-asserted-by":"crossref","first-page":"123","DOI":"10.14740\/wjon1210","article-title":"Non-muscle invasive bladder cancer:A review of the current trend in Africa","volume":"10","author":"Cassell","year":"2019","journal-title":"World J Oncol"},{"key":"R3-20240907","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bju.14417","article-title":"A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens","volume":"123","author":"Mari","year":"2019","journal-title":"BJU Int"},{"key":"R4-20240907","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/bjc.2013.372","article-title":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder","volume":"109","author":"Xylinas","year":"2013","journal-title":"Br J Cancer"},{"key":"R5-20240907","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00345-018-2503-4","article-title":"Molecular markers in bladder cancer","volume":"37","author":"Soria","year":"2019","journal-title":"World J Urol"},{"key":"R6-20240907","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ejso.2018.02.209","article-title":"Inflammation and cancer:What a surgical oncologist should know","volume":"44","author":"Dupr\u00e9A","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"R7-20240907","doi-asserted-by":"crossref","first-page":"863","DOI":"10.31557\/APJCP.2019.20.3.863","article-title":"Pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as a predictive value of hematological markers in cervical cancer","volume":"20","author":"Prabawa","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"key":"R8-20240907","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/01635581.2020.1737155","article-title":"Prognostic value of pretreatment albumin to globulin ratio in lung cancer:A meta-analysis","volume":"73","author":"Li","year":"2021","journal-title":"Nutrition Cancer"},{"key":"R9-20240907","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder:Update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"R11-20240907","author":"Sauter","year":"2004","journal-title":"Non-invasive urothelial tumours"},{"key":"R12-20240907","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.urolonc.2016.05.013","article-title":"Prognostic significance of markers of systemic inflammatory response in patients with non\u2013muscle-invasive bladder cancer","volume":"34","author":"Mbeutcha","year":"2016","journal-title":"Urol Oncol"},{"key":"R13-20240907","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tranon.2016.10.006","article-title":"Preoperative monocyte-to-lymphocyte ratio in peripheral blood predicts stages, metastasis, and histological grades in patients with ovarian cancer","volume":"10","author":"Xiang","year":"2017","journal-title":"Transl Oncol"},{"key":"R14-20240907","doi-asserted-by":"crossref","first-page":"6036979","DOI":"10.1155\/2019\/6036979","article-title":"Combined diagnostic efficacy of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV) as biomarkers of systemic inflammation in the diagnosis of colorectal cancer","volume":"2019","author":"Stojkovic Lalosevic","year":"2019","journal-title":"Dis Markers"},{"key":"R15-20240907","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1007\/s00345-020-03586-1","article-title":"Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer","volume":"39","author":"Quhal","year":"2021","journal-title":"World J Urol"},{"key":"R16-20240907","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.euo.2018.06.006","article-title":"Systemic inflammatory markers and oncologic outcomes in patients with high-risk non\u2013muscle-invasive urothelial bladder cancer","volume":"1","author":"Cantiello","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"R17-20240907","doi-asserted-by":"crossref","first-page":"e14420","DOI":"10.1097\/MD.0000000000014420","article-title":"Prognostic significance of inflammation-based indexes in patients with stage III\/IV colorectal cancer after adjuvant chemoradiotherapy","volume":"98","author":"Yang","year":"2019","journal-title":"Medicine"},{"key":"R18-20240907","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables:A combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"R19-20240907","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/14737159.2018.1453808","article-title":"Waiting in the wings:The emerging role of molecular biomarkers in bladder cancer","volume":"18","author":"Ilijazi","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"R20-20240907","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1541-7786.MCR-05-0261","article-title":"Inflammation, a key event in cancer development","volume":"4","author":"Lu","year":"2006","journal-title":"Mol Cancer Res"},{"key":"R21-20240907","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jcp.10014","article-title":"Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3:A role for inflammatory cells in tumor invasion and angiogenesis","volume":"189","author":"Shamamian","year":"2001","journal-title":"J Cell Physiol"},{"key":"R22-20240907","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3390\/ijms19020448","article-title":"Apoptosis:A target for anticancer therapy","volume":"19","author":"Pfeffer","year":"2018","journal-title":"Int J Mol Sci."},{"key":"R23-20240907","doi-asserted-by":"crossref","first-page":"e755","DOI":"10.1016\/j.clgc.2017.03.007","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in primary non\u2013muscle-invasive bladder cancer","volume":"15","author":"D'Andrea","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"R24-20240907","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.semcancer.2011.12.005","article-title":"Cancer-related inflammation:Common themes and therapeutic opportunities","volume":"22","author":"Balkwill","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"R25-20240907","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1016\/j.clgc.2017.12.013","article-title":"Prognostic value of pretreatment albumin-to-globulin ratio in patients with non\u2013muscle-invasive bladder cancer","volume":"16","author":"Niwa","year":"2018","journal-title":"Clin Genitourin Cancer"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_399_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:14:15Z","timestamp":1787760855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_399_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_399_22","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"2022-06-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}